Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

NCT06221683 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

AML, Childhood
Acute Myeloid Leukemia

Interventions

DRUG: Homoharringtonine
DRUG: Cytarabine
DRUG: Etoposide
DRUG: Venetoclax
DRUG: Mitoxantrone hydrochloride liposome
DRUG: Recombinant Human Granulocyte Colony-Stimulating Factor
DRUG: Idarubicin Hydrochloride
DRUG: Sorafenib
DRUG: Gilteritinib
DRUG: Avapritinib

Sponsor

Children's Hospital of Soochow University